COMMUNIQUÉS West-GlobeNewswire

Avalyn Appoints Industry Veterans Jill Denning and Kimberley Cummings to Leadership
01/10/2025
Appointments expand clinical and regulatory capabilities ahead of key program milestones BOSTON, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. , a clinical-stage biopharmaceutical company focused on the [...]
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
01/10/2025
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting [...]
Starton Therapeutics to Participate in Panel at Longwood Healthcare Leaders Boston CEO, October 27-28, 2025
01/10/2025
PARAMUS, N.J., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, [...]
Alignment Health Unveils 2026 Medicare Advantage Plans with Strong Benefits, Expanded Support for Seniors
01/10/2025
Plans to reach nearly 8.3 million Medicare-eligible adults across five states during annual enrollment period, Oct. 15-Dec. 7 ORANGE, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Alignment Health Plan , an award-winning [...]
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
01/10/2025
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S. Food and Drug [...]
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
01/10/2025
CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and [...]
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
01/10/2025
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3% [...]
Myrtelle Announces Nature Medicine Publication of Interim Results from Its Phase 1/2 Clinical Trial of Investigational Gene Therapy rAAV-Olig001-ASPA for Canavan Disease
01/10/2025
Groundbreaking study demonstrates that targeted oligodendrocyte gene therapy leads to decreased N-acetylaspartate (NAA) levels and increased brain myelin volume, resulting in promising functional improvements in [...]
Primary.Health Launches Nation's First Advanced Newborn Screening Case Management Platform
01/10/2025
Primary’s cloud-based system modernizes state newborn screening tracking and follow-up, incorporating cutting-edge science, evidence-based clinical protocols, and emerging screening methodologies to ensure no baby falls [...]
Maxion Therapeutics Appoints Joel Edwards as Chief Business Officer
01/10/2025
Cambridge, UK, 1 October 2025 – Maxion Therapeutics (“Maxion”), a biotechnology company developing antibody-based KnotBody® drugs for ion channel and G protein coupled receptor (GPCR)-driven diseases, today announces [...]
Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa
01/10/2025
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced its upcoming [...]
TOMI Environmental Solutions Announces $175,000 Equipment Purchase by T.A.C.T., Signaling Continued Demand in Commercial Sector
01/10/2025
Strategic Expansion with Leading Franchise Network Underscores Revenue Potential and Market Leadership for SteraMist iHP Technology FREDERICK, Md., Oct. 01, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc [...]
CMS New Technology Add-On Payment Expands Access to RECELL® for Patients with Non-Burn Acute Wounds
01/10/2025
Hospitals may receive up to $4,875 in added reimbursement when using RECELL to treat non-burn full-thickness acute wounds resulting from trauma or surgery Effective October 1, the add-on payment eases financial barriers [...]
Profusa Adds a Leading French Critical Limb Ischemia Surgeon to Customer Base
01/10/2025
Pr. Yann Gouëffic and affiliates (FRANCE-PAD) cover ~8% of all CLTI cases in France BERKELEY, Calif, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage [...]
Dr. Anosh Ahmed Foundation and CEO: Anosh Ahmed Commits $1M Investment in ReliefWings to Advance Humanitarian Aid
01/10/2025
AI-powered drone network aims to deliver food, medicine, and emergency supplies to flood-affected and hard-to-reach communities Anosh Ahmed invests in ReliefWings' AI-powered drones to deliver aid. DUBAI, United Arab [...]
Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million
01/10/2025
- Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market - GAITHERSBURG, Md., Oct. 01, 2025 ( [...]
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
01/10/2025
Los Angeles, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other [...]
Microbot Medical® Receives First Patent in Japan as it Continues to Broaden its Global Intellectual Property Portfolio
01/10/2025
Commercial Focus Remains on U.S. Market as it Continues to Explore Certain Global Markets that Accept FDA Cleared Devices Protecting its Innovative Technology Remains a Priority and Momentum Increasing as Global [...]
SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions
01/10/2025
Represents potential penetration into ~ 20% of the U.S. institutional market, while broadening access across long-term care and outpatient facilities U.S. losartan market totals $256M annually with 71M prescriptions, [...]

Pages